Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-20.15	-22.21	-29.22	-25.43	-10.93
Depreciation & Amortization	1.22	1.54	1.26	0.25	0.16
Stock-Based Compensation	2.28	2.96	4.81	4.52	1.33
Other Adjustments	0.09	-0.28	2.41	3.87	0.58
Changes in Accounts Payable	-2.09	-0.63	-6.17	1.62	-0.24
Changes in Accrued Expenses	-1.75	-1.85	1.28	1.78	1.75
Changes in Other Operating Activities	-1.62	0.78	-1.35	0.17	-0.41
Operating Cash Flow	-21.67	-19.69	-26.98	-13.21	-7.77
Capital Expenditures	-0.1	-0.02	-0.59	-0.43	-0.21
Other Investing Activities	-	-	0.11	-0.07	-0.01
Investing Cash Flow	-0.1	-0.02	-0.48	-0.49	-0.22
Short-Term Debt Issued	-	0.8	-	-	0.38
Short-Term Debt Repaid	-0.38	-0.08	-0.1	-0.08	-0.03
Net Short-Term Debt Issued (Repaid)	-0.38	0.72	-0.1	-0.08	0.35
Long-Term Debt Issued	-	3	6.01	12.15	9.43
Long-Term Debt Repaid	-2.06	-1.8	-2.25	-0.04	-0.1
Net Long-Term Debt Issued (Repaid)	-2.06	1.2	3.76	12.11	9.33
Issuance of Common Stock	38.97	25.01	3.04	0.11	0.14
Net Common Stock Issued (Repurchased)	38.97	25.01	3.04	0.11	0.14
Issuance of Preferred Stock	-	-	24.5	-	-
Net Preferred Stock Issued (Repurchased)	-	-	24.5	-	-
Other Financing Activities	-1.23	0.44	-2.16	-0.06	-
Financing Cash Flow	30.23	27.37	29.04	12.09	9.81
Net Cash Flow	8.46	7.66	1.58	-1.62	1.82
Free Cash Flow	-21.77	-19.71	-27.57	-13.64	-7.98
FCF Margin	-	-	-	-30315.56%	-1777.28%
Free Cash Flow Per Share	-7.70	-29.55	-195.52	-192.59	-48.49
Levered Free Cash Flow	-32.3	-22.08	-31.13	-10	-0.21
Unlevered Free Cash Flow	-24.16	-21.97	-34.58	-19.74	-9.45

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q